Search
Search
About
Log in
Join
Experiences with
Dabrafenib
Posts
Communities
4 public posts
Filter results
BRA/ Mek Treatment holiday flops in late stage melanoma trial
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of
dabrafenib
(Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of
dabrafenib
(Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported
missyrand
Ambassador
in
Melanoma Caregivers
4 years ago
BRAF/MEK combo raises risk of cardiovascular adverse events compared to BRAF monotherapy only
Three BRAF inhibitors --
dabrafenib
, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
Three BRAF inhibitors --
dabrafenib
, vemurafenib, and encorafenib -- are now approved by the FDA and the European Medicines Agency, as are three MEK inhibitors -- trametinib, cobimetinib, and binimetinib.
missyrand
Ambassador
in
Melanoma Caregivers
5 years ago
Do you know your tumor BRAF status? You probably should
Combined BRAF/MEK inhibition is an option that is recommended for BRAF-mutant patients, in light of the COMBI-AD study which showed higher relapse-free survival at 4 years with
dabrafenib
and trametinib compared with treatment with placebo.
Combined BRAF/MEK inhibition is an option that is recommended for BRAF-mutant patients, in light of the COMBI-AD study which showed higher relapse-free survival at 4 years with
dabrafenib
and trametinib compared with treatment with placebo.
missyrand
Ambassador
in
Melanoma Caregivers
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
GREAT NEWS: HEALTH CANADA APPROVES FIRST ADJUVANT TREATMENT FOR MELANOMA TO PREVENT RELAPSE FOLLOWING SURGERY!
Health Canada has just approved the use of a combination therapy of Tafinlar® (
dabrafenib
) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment.
Health Canada has just approved the use of a combination therapy of Tafinlar® (
dabrafenib
) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment.
amykjones
Administrator
in
Melanoma Wellness Canada
6 years ago
Filter results
Clear filters
Posted in
All communities
Melanoma Caregivers
3 results
Melanoma Wellness Canada
1 result
Sort by
Most Relevant
Newest